These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 20298568)

  • 21. Metformin extended release--DepoMed: metformin, metformin gastric retention, metformin GR.
    Drugs R D; 2004; 5(4):231-3. PubMed ID: 15230631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bioequivalence and Food Effect of Dapagliflozin/Saxagliptin/Metformin Extended-release Fixed-combination Drug Products Compared With Coadministration of the Individual Components in Healthy Subjects.
    Tang W; Engman H; Zhu Y; Dayton B; Boulton DW
    Clin Ther; 2019 Aug; 41(8):1545-1563. PubMed ID: 31266654
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improving Type 2 Diabetes Care with Extended-Release Metformin: Real-Life Insights from a Physician Educational Program.
    Molteni L; Marelli G; Castagna G; Brambilla L; Acerbis M; Alberghina F; Carpani A; Chiavenna E; Ferlini MG; Impellizzeri C; Paredi R; Rigamonti A; Rivolta G; Disoteo OE
    Endocr Metab Immune Disord Drug Targets; 2024; 24(12):1422-1430. PubMed ID: 38425116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and Side Effect Profile of Different Formulations of Metformin: A Systematic Review and Meta-Analysis.
    Tarry-Adkins JL; Grant ID; Ozanne SE; Reynolds RM; Aiken CE
    Diabetes Ther; 2021 Jul; 12(7):1901-1914. PubMed ID: 34075573
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adherence, satisfaction, and experience with metformin 500 mg prolonged release formulation in Indian patients with type 2 diabetes mellitus: a postmarketing observational study.
    Kumar KMP; Chawla M; Sanghvi A; Sastry NG; Kotla C; Phatak S; Choudhari S
    Int J Gen Med; 2019; 12():147-159. PubMed ID: 31040711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy.
    Chacra AR
    Am J Ther; 2014; 21(3):198-210. PubMed ID: 22314210
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Once-daily delayed-release metformin lowers plasma glucose and enhances fasting and postprandial GLP-1 and PYY: results from two randomised trials.
    DeFronzo RA; Buse JB; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetologia; 2016 Aug; 59(8):1645-54. PubMed ID: 27216492
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term tolerability and safety of lamotrigine extended-release: pooled analysis of three clinical trials.
    Biton V; Shneker BF; Naritoku D; Hammer AE; Vuong A; Caldwell PT; Messenheimer JA
    Clin Drug Investig; 2013 May; 33(5):359-64. PubMed ID: 23475541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feasibility trial of metformin XR in people with pre-diabetes and stroke (MIPPS)-randomised open blinded endpoint controlled trial.
    Tabesh M; Hachem M; Lau LH; Borschmann K; Churilov L; Price SAL; Sumithran P; Donnan G; Zajac J; Thijs V; Ekinci EI
    J Clin Neurosci; 2021 Apr; 86():103-109. PubMed ID: 33775312
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
    Balasubramanian R; Varadharajan S; Kathale A; Nagraj LM; Periyandavar I; Nayak UP; Sharma A; Bolmall C; Baliga VP
    J Indian Med Assoc; 2008 Jul; 106(7):464-7. PubMed ID: 18975505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reactive Hypoglycemia From Metformin Immediate-Release Monotherapy Resolved by a Switch to Metformin Extended-Release: Conceptualizing Their Concentration-Time Curves.
    Akram A
    Cureus; 2021 Jul; 13(7):e16112. PubMed ID: 34350076
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Post-marketing experience with nevirapine extended release (XR) tablets: effectiveness and tolerability in a population-based cohort in British Columbia, Canada.
    Lepik KJ; Yip B; McGovern RA; Ding E; Nohpal A; Watson BE; Toy J; Akagi L; Harrigan PR; Moore DM; Hogg RS; Montaner JS; Barrios R
    Antivir Ther; 2015; 20(7):721-30. PubMed ID: 25960569
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetic simulations of topiramate plasma concentrations following dosing irregularities with extended-release vs. immediate-release formulations.
    Brittain ST; Wheless JW
    Epilepsy Behav; 2015 Nov; 52(Pt A):31-6. PubMed ID: 26409125
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
    Buse JB; DeFronzo RA; Rosenstock J; Kim T; Burns C; Skare S; Baron A; Fineman M
    Diabetes Care; 2016 Feb; 39(2):198-205. PubMed ID: 26285584
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Short-term therapy with combination dipeptidyl peptidase-4 inhibitor saxagliptin/metformin extended release (XR) is superior to saxagliptin or metformin XR monotherapy in prediabetic women with polycystic ovary syndrome: a single-blind, randomized, pilot study.
    Elkind-Hirsch KE; Paterson MS; Seidemann EL; Gutowski HC
    Fertil Steril; 2017 Jan; 107(1):253-260.e1. PubMed ID: 28228317
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
    Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
    Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes.
    Lingvay I; Beetz N; Sennewald R; Schuler-Metz A; Bertulis J; Loley C; Lang B; Lippert C; Lee J; Manning LS; Terada D
    Postgrad Med; 2020 May; 132(4):337-345. PubMed ID: 32366156
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy, Safety, and Tolerability of an Extended-Release Orally Disintegrating Methylphenidate Tablet in Children 6-12 Years of Age with Attention-Deficit/Hyperactivity Disorder in the Laboratory Classroom Setting.
    Childress AC; Kollins SH; Cutler AJ; Marraffino A; Sikes CR
    J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):66-74. PubMed ID: 27183299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A randomized trial of dapagliflozin and metformin, alone and combined, in overweight women after gestational diabetes mellitus.
    Elkind-Hirsch KE; Seidemann E; Harris R
    Am J Obstet Gynecol MFM; 2020 Aug; 2(3):100139. PubMed ID: 33345876
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.